MX391935B - Anticuerpos inhibidores de via del factor tisular y usos de los mismos. - Google Patents

Anticuerpos inhibidores de via del factor tisular y usos de los mismos.

Info

Publication number
MX391935B
MX391935B MX2018002048A MX2018002048A MX391935B MX 391935 B MX391935 B MX 391935B MX 2018002048 A MX2018002048 A MX 2018002048A MX 2018002048 A MX2018002048 A MX 2018002048A MX 391935 B MX391935 B MX 391935B
Authority
MX
Mexico
Prior art keywords
tissue factor
pathway inhibitor
factor pathway
inhibitor antibodies
antibodies
Prior art date
Application number
MX2018002048A
Other languages
English (en)
Other versions
MX2018002048A (es
Inventor
Debra Pittman
Gregory J Carven
Zong Sean Juo
James R Apgar
Macy Jin
Mark Stahl
Matthew Holsti
Reema Jasuja
Sunita R Hett
Susan Benard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2018002048A publication Critical patent/MX2018002048A/es
Publication of MX391935B publication Critical patent/MX391935B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a un anticuerpo aislado o fragmento de unión a antígeno del mismos que se une de manera específica a un epítope en el Dominio Kunitz 2 (K2) del Inhibidor de Vía del Factor Tisular (TFPI), caracterizado porque dicho anticuerpo es seleccionado a partir del grupo que consiste en un anticuerpo que comprende: (a) una región variable de cadena pesada (VH) que comprende una región determinante de complementariedad VH 1 (CDR-H1) que comprende la secuencia de aminoácido de SEQ ID NO: 38, una CDR-H2 que comprende la secuencia de aminoácido de SEQ ID NO: 39 y una CDR-H3 que comprende la secuencia de aminoácido de SEQ ID NO: 40; y una región de cadena ligera variable (VL) que comprende una región determinante de complementariedad VL 1 (CDR-L1) que comprende la secuencia de aminoácidos de SEQ ID NO: 33, una CDR-L2 que comprende la secuencia de aminoácidos de SEQ ID NO: 34 y una CDR-L3 que comprende la secuencia de aminoácidos de SEQ ID NO: 35, (b) una VH que comprende la secuencia de aminoácidos de SEQ ID NO: 63 y una VL que comprende la secuencia de aminoácidos de SEQ ID NO: 36; (d) una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID NO: 64 y una cadena ligera que comprende la secuencia de aminoácidos de SEQ ID NO: 37; ( e) una cadena pesad que comprende la secuencia de aminoácidos de SEQ ID NO: 42 y una cadena ligera que comprende la secuencia de aminoácidos de SEQ ID NO: 37.
MX2018002048A 2015-08-19 2016-08-10 Anticuerpos inhibidores de via del factor tisular y usos de los mismos. MX391935B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207229P 2015-08-19 2015-08-19
US201662360205P 2016-07-08 2016-07-08
PCT/IB2016/054814 WO2017029583A2 (en) 2015-08-19 2016-08-10 Tissue factor pathway inhibitor antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2018002048A MX2018002048A (es) 2018-04-13
MX391935B true MX391935B (es) 2025-03-21

Family

ID=56894019

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002048A MX391935B (es) 2015-08-19 2016-08-10 Anticuerpos inhibidores de via del factor tisular y usos de los mismos.
MX2022004834A MX2022004834A (es) 2015-08-19 2018-02-16 Anticuerpos inhibidores de via del factor tisular y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004834A MX2022004834A (es) 2015-08-19 2018-02-16 Anticuerpos inhibidores de via del factor tisular y usos de los mismos.

Country Status (21)

Country Link
US (5) US10550200B2 (es)
EP (2) EP3337827B1 (es)
JP (4) JP6664467B2 (es)
KR (4) KR20230074843A (es)
CN (2) CN114163531B (es)
AU (2) AU2016307967C9 (es)
CA (2) CA3174958C (es)
CO (1) CO2018001473A2 (es)
DK (1) DK3337827T3 (es)
IL (3) IL302353A (es)
MX (2) MX391935B (es)
MY (1) MY195443A (es)
NZ (1) NZ739871A (es)
PE (2) PE20240142A1 (es)
PH (1) PH12018500211A1 (es)
RU (1) RU2705540C2 (es)
SA (1) SA518390944B1 (es)
SG (1) SG10201912817YA (es)
TW (1) TWI640538B (es)
WO (1) WO2017029583A2 (es)
ZA (1) ZA201800453B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072691A1 (en) † 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
EP3337827B1 (en) 2015-08-19 2026-07-08 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
EP3863664A1 (en) * 2018-10-11 2021-08-18 Pfizer Inc. Dosage regimen for tfpi antagonists
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
US20220324957A1 (en) 2019-09-16 2022-10-13 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease
AU2020385048A1 (en) * 2019-11-13 2022-06-02 Pfizer Inc. Stable aqueous anti-TFPI antibody formulation
KR102140653B1 (ko) 2020-01-13 2020-08-03 이선재 떡 연속증숙장치
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
WO2022097065A2 (en) * 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
CN113325185B (zh) * 2021-07-09 2024-04-19 重庆鼎润医疗器械有限责任公司 多水平质控品及其制备方法和在血栓弹力图检测上的应用
EP4453012A1 (en) 2021-12-22 2024-10-30 Royal College of Surgeons in Ireland A conjugate for use in localising a molecule to the vascular endothelium
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技(上海)有限公司 针对tfpi的单克隆抗体及其用途
CN116903739B (zh) * 2023-03-28 2023-12-15 中国人民解放军军事科学院军事医学研究院 一种抗s100b蛋白的抗体及其应用
CN122396505A (zh) * 2023-12-13 2026-07-14 苏州康宁杰瑞生物科技有限公司 Tfpi抗体用于治疗血友病

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
JP4340339B2 (ja) * 1998-07-31 2009-10-07 財団法人化学及血清療法研究所 血液凝固因子もしくは血液凝固制御因子欠損モデル動物並びに該モデル動物の作製方法
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CN101883793A (zh) * 2007-08-23 2010-11-10 Lfb生物科技公司 中和针对因子ⅷ的c1结构域的抑制性抗体的抑制活性的抗独特型抗体
FR2933908B1 (fr) 2008-07-16 2010-12-24 Renault Sas Dispositif de protection pour une porte de vehicule automobile.
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2379096B1 (en) * 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
WO2010072687A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
ES2983470T3 (es) * 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
TW201212938A (en) 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
ES2722824T3 (es) * 2011-04-01 2019-08-19 Bayer Healthcare Llc Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
WO2013023251A1 (en) 2011-08-18 2013-02-21 Affinity Biosciences Pty Ltd Soluble polypeptides
WO2013148248A1 (en) 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9896513B2 (en) 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
CN113788897A (zh) 2013-03-15 2021-12-14 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
EP2970498A4 (en) 2013-03-15 2016-11-23 Bayer Healthcare Llc PRODUCT ANTIBODIES DIRECTED AGAINST THE INHIBITOR OF THE PATHWAY OF TISSUE FACTOR
WO2015007880A1 (en) 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
EP3225630B1 (en) 2014-11-27 2021-05-12 Public University Corporation Yokohama City University Method and reagent for detecting ovarian clear cell adenocarcinoma
MX388251B (es) 2015-02-25 2025-03-19 Mogam Inst Biomedical Res Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
EP3337827B1 (en) * 2015-08-19 2026-07-08 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
EP3863664A1 (en) 2018-10-11 2021-08-18 Pfizer Inc. Dosage regimen for tfpi antagonists

Also Published As

Publication number Publication date
PE20180556A1 (es) 2018-04-02
CA2939010C (en) 2025-09-16
US20210101998A1 (en) 2021-04-08
US10550200B2 (en) 2020-02-04
US10875929B2 (en) 2020-12-29
TW201718659A (zh) 2017-06-01
RU2018104283A3 (es) 2019-09-19
SA518390944B1 (ar) 2022-02-08
NZ739871A (en) 2022-05-27
JP7303761B2 (ja) 2023-07-05
KR102536303B1 (ko) 2023-05-26
BR112018001478A2 (pt) 2018-09-18
KR20220136381A (ko) 2022-10-07
MX2018002048A (es) 2018-04-13
EP3337827B1 (en) 2026-07-08
IL256913A (en) 2018-03-29
CN114163531B (zh) 2025-06-13
NZ756365A (en) 2025-02-28
US12168698B2 (en) 2024-12-17
KR102068915B1 (ko) 2020-01-22
EP4792830A2 (en) 2026-08-19
PH12018500211A1 (en) 2018-08-13
IL256913B (en) 2022-02-01
AU2016307967C9 (en) 2025-02-20
JP6664467B2 (ja) 2020-03-13
CN107922506B (zh) 2021-11-09
KR102068915B9 (ko) 2023-10-12
JP7854307B2 (ja) 2026-05-01
KR20230074843A (ko) 2023-05-31
CN107922506A (zh) 2018-04-17
CA3174958C (en) 2025-05-27
MX2022004834A (es) 2022-05-16
US11634504B2 (en) 2023-04-25
IL289766B1 (en) 2023-06-01
JP2022084623A (ja) 2022-06-07
WO2017029583A3 (en) 2017-07-20
US20200190214A1 (en) 2020-06-18
IL289766A (en) 2022-03-01
CO2018001473A2 (es) 2018-05-10
EP3337827A2 (en) 2018-06-27
RU2018104283A (ru) 2019-09-19
IL289766B2 (en) 2023-10-01
CN114163531A (zh) 2022-03-11
JP2020096627A (ja) 2020-06-25
WO2017029583A2 (en) 2017-02-23
AU2022201091A1 (en) 2022-03-10
US20170073428A1 (en) 2017-03-16
CA2939010A1 (en) 2017-02-19
DK3337827T3 (da) 2026-07-27
IL302353A (en) 2023-06-01
KR20180030936A (ko) 2018-03-26
KR102438650B1 (ko) 2022-08-31
JP2018527922A (ja) 2018-09-27
KR20190097319A (ko) 2019-08-20
MY195443A (en) 2023-01-21
RU2705540C2 (ru) 2019-11-07
US20250145732A1 (en) 2025-05-08
AU2016307967C1 (en) 2023-10-05
CA3174958A1 (en) 2017-02-19
AU2016307967A1 (en) 2018-02-01
PE20240142A1 (es) 2024-02-01
TWI640538B (zh) 2018-11-11
JP2024054266A (ja) 2024-04-16
SG10201912817YA (en) 2020-02-27
AU2016307967B2 (en) 2022-02-17
AU2022201091B2 (en) 2025-03-20
ZA201800453B (en) 2018-12-19
US20230416405A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
CY1125327T1 (el) Anti-pd-1 αντισωματα και συνθεσεις
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
MX2016014140A (es) Composiciones y metodos para modular la expresion de pkk.
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
MX376201B (es) Compuestos inhibidores de metaloenzima.
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
EA201691541A1 (ru) Новые анти-baff антитела
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
MX380669B (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
MX2017003211A (es) Anticuerpos anti-met y composiciones.
MX2019007892A (es) Compuestos inhibidores de metaloenzimas.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX386860B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX373805B (es) Agonistas de receptor fgf21 y usos del mismo.
EA201690557A1 (ru) Способы лечения синдрома ломкой х-хромосомы и связанных расстройств